Patents Assigned to Agensys, Inc.
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20210188985
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 24, 2021
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane Meyrick MORRISON
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20210188984
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 24, 2021
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane Meyrick MORRISON
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20210145979
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: April 17, 2020
    Publication date: May 20, 2021
    Applicant: AGENSYS, INC.
    Inventors: Daniel Sousa PEREIRA, Faisal Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20210095043
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: May 4, 2020
    Publication date: April 1, 2021
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 10894090
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: January 19, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES
    Publication number: 20200325170
    Abstract: Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.
    Type: Application
    Filed: November 14, 2019
    Publication date: October 15, 2020
    Applicant: AGENSYS, INC.
    Inventors: Brian Alan MENDELSOHN, Julien DUGAL-TESSIER, Stuart Daniel BARNSCHER
  • Antibodies that bind to AXL proteins
    Patent number: 10787516
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 29, 2020
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Antibodies that bind to AXL proteins
    Patent number: 10787517
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 29, 2020
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Antibody drug conjugates (ADC) that bind to FLT3 proteins
    Patent number: 10751422
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: August 25, 2020
    Assignee: AGENSYS, INC.
    Inventors: Nandini Rudra-Ganguly, Christine Lowe, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
  • ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS
    Publication number: 20200247905
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Application
    Filed: February 13, 2020
    Publication date: August 6, 2020
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Soudabeh ETESSAMI, Pia M. CHALLITA-EID, Juan J. PEREZ-VILLAR, Karen J. MORRISON, Xiao-Chi JIA, Mary FARIS, Jean GUDAS, Arthur B. RAITANO
  • NECTIN-4 BINDING PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20200231670
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Nectin-4. Also provided herein are methods for assessing Nectin-4 expression in a sample or a patient and methods for assessing responsiveness of a cancer patient to an anti-cancer therapeutic agent.
    Type: Application
    Filed: June 4, 2018
    Publication date: July 23, 2020
    Applicant: AGENSYS, INC.
    Inventors: Karen Jane Meyrick MORRISON, Fernando DONATE, Peng YANG
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 10669348
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: June 2, 2020
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 10646583
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: May 12, 2020
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 10597463
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: March 24, 2020
    Assignee: AGENSYS, INC.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Antibody drug conjugates (ADC) that bind to FLT3 proteins
    Patent number: 9974865
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 22, 2018
    Assignee: AGENSYS, INC.
    Inventors: Christine Lowe, Nandini Rudra-Ganguly, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20180134792
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: May 18, 2016
    Publication date: May 17, 2018
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane, Meyrick MORRISON
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20180134793
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: May 18, 2016
    Publication date: May 17, 2018
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane, Meyrick MORRISON
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9962454
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 8, 2018
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: RE47103
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 30, 2018
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: RE48389
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: January 12, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An